Lipoxins and synthetic lipoxin mimetics: Therapeutic potential in renal diseases

Darrell Andrews1, Catherine Godson1

  • 1Diabetes Complications Research Centre, Conway Institute and School of Medicine, University College Dublin, Dublin, Ireland.

Insights

Specialized pro-resolving lipid mediators, including lipoxins, promote inflammation resolution and tissue repair. Research explores harnessing lipoxins for kidney disease therapy, offering an alternative to conventional anti-inflammatories with fewer side effects.

Area of Science:

  • Renal pathology
  • Inflammation resolution
  • Lipid mediator biochemistry

Background:

  • Effective host defense and tissue repair depend on timely inflammation resolution.
  • Unresolved inflammation is a hallmark of many kidney diseases.
  • Conventional anti-inflammatory drugs can cause immunosuppression and other side effects.

Purpose of the Study:

  • To discuss the pro-resolving bioactions of specialized pro-resolving mediators (SPMs), such as lipoxins.
  • To review recent research on utilizing lipoxins therapeutically for kidney disease.

Main Methods:

  • Literature review of inflammation resolution mechanisms.
  • Analysis of studies investigating lipoxin bioactions.
  • Exploration of therapeutic strategies for kidney disease using SPMs.

Main Results:

  • Lipoxins and other SPMs actively promote inflammation resolution and endogenous repair.
  • SPMs offer a mechanism to resolve inflammation without compromising host defense.
  • Emerging research highlights the potential of lipoxins in managing renal pathologies.

Conclusions:

  • Lipoxins represent a promising therapeutic avenue for kidney diseases characterized by unresolved inflammation.
  • Harnessing SPM pathways may provide a safer alternative to conventional anti-inflammatory treatments.
  • Further research is warranted to fully elucidate and exploit the therapeutic potential of lipoxins in nephrology.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
650
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
588
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.6K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
977
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
1.8K